Integrated analysis of immune-related long noncoding RNAs as diagnostic biomarkers in psoriasis

Fan Feixiang, Zhen Huang, Yongfeng Chen

1 Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China
2 Department of Dermatology, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong, China

Corresponding Author: Yongfeng Chen
Email address: gdcyf@163.com

Abstract Background: Psoriasis is a chronic immune-mediated inflammatory dermatosis. Long noncoding RNAs (IncRNAs) play an important role in immune-related diseases. This study aimed to identify potential immune-related IncRNA biomarkers for psoriasis.

Methods: We screened differentially expressed immune-related IncRNAs biomarkers using GSE13355 (skin biopsy samples of 180 cases) from Gene Expression Omnibus (GEO). Moreover, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) were performed to explore biological mechanisms in psoriasis. In addition, we performed LASSO logistic regression to identify potential diagnostic IncRNAs and further verify the diagnostic value and relationship with drug response using two validation sets GSE30999 (skin biopsy samples of 170 cases) and GSE106992 (skin biopsy samples of 192 cases). Furthermore, we estimated the degree of infiltrated immune cells and investigated the correlation between infiltrated immune cells and diagnostic IncRNA biomarkers.

Results: A total of 394 differentially expressed genes (DEGs) were extracted from gene expression profile. GO and KEGG analysis of target genes found that immune-related IncRNAs were primarily associated with epidermis development, skin development, collagen-containing extracellular matrix, and glycosaminoglycan binding and mainly enriched in cytokine-cytokine receptor interaction and influenza A and chemokine signaling pathway. We found that LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMN, CCDC18-AS1, EPB41L4A-AS1, and LINC01214 exhibited well diagnostic efficacy. The ROC and ROC CI were 0.944 (0.907–0.982), 0.953 (0.919–0.987), 0.822 (0.758–0.887), 0.854 (0.797–0.911), 0.957(0.929–0.985), 0.894 (0.846–0.942), and 0.964 (0.937–0.991) for LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMN, CCDC18-AS1, EPB41L4A-AS1, and LINC01214. LINC01137, LINC01215, and LINC01214 were correlated with drug response. LINC01137, CCDC18-AS1, and CARMN were positively correlated with activated memory CD4 T cell, activated myeloid dendritic cell (DC), neutrophils, macrophage M1, and T follicular helper (Tfh) cells, while negatively
correlated with T regulatory cell (Treg). LINC01215, MAPKAPK5-AS1, TPT1-AS1, EPB41L4A-AS, and LINC01214 were negatively correlated with activated memory CD4 T cell, activated myeloid DC, neutrophils, macrophage M1, and Tfh, while positively correlated with Treg. **Conclusions:** These findings indicated that these immune-related lncRNAs may be used as potential diagnostic and predictive biomarkers for psoriasis.
Integrated analysis of immune-related long noncoding RNAs as diagnostic biomarkers in psoriasis

Feixiang Fan¹², Zhen Huang², Yongfeng Chen¹

¹Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China
²Department of Dermatology, Shenzhen Longhua District Central Hospital, Shenzhen, Guangdong, China

Corresponding Author:
Yongfeng Chen
Lujing Road, No. 2, Guangzhou, Guangdong, 510091, China
Email address: gdcyf@163.com

Abstract

Background: Psoriasis is a chronic immune-mediated inflammatory dermatosis. Long noncoding RNAs (lncRNAs) play an important role in immune-related diseases. This study aimed to identify potential immune-related lncRNA biomarkers for psoriasis.

Methods: We screened differentially expressed immune-related lncRNAs biomarkers using GSE13355 (skin biopsy samples of 180 cases) from Gene Expression Omnibus (GEO). Moreover, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA) were performed to explore biological mechanisms in psoriasis. In addition, we performed LASSO logistic regression to identify potential diagnostic lncRNAs and further verify the diagnostic value and relationship with drug response using two validation sets GSE30999 (skin biopsy samples of 170 cases) and GSE106992 (skin biopsy samples of 192 cases). Furthermore, we estimated the degree of infiltrated immune cells and investigated the correlation between infiltrated immune cells and diagnostic lncRNA biomarkers.

Results: A total of 394 differentially expressed genes (DEGs) were extracted from gene expression profile. GO and KEGG analysis of target genes found that immune-related lncRNAs were primarily associated with epidermis development, skin development, collagen-containing extracellular matrix, and glycosaminoglycan binding and mainly enriched in cytokine-cytokine receptor interaction and influenza A and chemokine signaling pathway. We found that LINC01137, LINC01215, MAPKAP5-AS1, TPT1-AS1, CARMN, CCDC18-AS1, EPB41L4A-AS, and LINC01214 exhibited well diagnostic efficacy. The ROC and ROC CI were 0.944 (0.907–0.982), 0.953 (0.919–0.987), 0.822 (0.758–0.887), 0.854 (0.797–0.911), 0.957(0.929–0.985), 0.894 (0.846–0.942), and 0.964 (0.937–0.991) for LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1,CARMN, CCDC18-AS1, EPB41L4A-AS1, and LINC01214. LINC01137, LINC01215, and LINC01214 were correlated with drug response. LINC01137, CCDC18-AS1, and CARMN were positively correlated with activated memory
CD4 T cell, activated myeloid dendritic cell (DC), neutrophils, macrophage M1, and T follicular helper (Tfh) cells, while negatively correlated with T regulatory cell (Treg). LINC01215, MAPKAPK5-AS1, TPT1-AS1, EPB41L4A-AS, and LINC01214 were negatively correlated with activated memory CD4 T cell, activated myeloid DC, neutrophils, macrophage M1, and Tfh, while positively correlated with Treg.

Conclusions: These findings indicated that these immune-related lncRNAs may be used as potential diagnostic and predictive biomarkers for psoriasis.

Introduction
Psoriasis is a chronic immune-mediated inflammatory dermatosis that affects 0.09%–5.1% of people worldwide, with incidence increasing annually (Boehncke & Schön, 2015; Michalek, Loring, & John, 2017). The patients’ quality of life is seriously affected because psoriasis is usually persistent and prone to relapse. The pathogenesis of psoriasis involves dysregulation of innate and adaptive immune system; however, the specific immunopathogenic mechanisms remain unclear (Albanesi et al., 2018). Therefore, investigation of immune-related diagnostic biomarkers and a better understanding of immunopathogenic mechanisms of psoriasis are important.

Long noncoding RNAs (lncRNAs) are transcripts longer than 200 nucleotides that generally do not code for proteins. They play pivotal roles in a number of physiological and pathological processes (Kopp & Mendell, 2018). Recent study has identified a variety of differentially expressed lncRNAs in psoriatic lesions that were changed after biologics therapy (Gupta et al., 2016). Previous studies focused on the correlation between lncRNAs and psoriatic keratinocytes (Duan et al., 2020); several lncRNAs, including TINCR, PRANCR and ANCR, played an important role in epidermal homeostasis (Cai et al., 2020; Kretz et al., 2013; Kretz et al., 2012). Research has revealed that PRINS is involved in psoriasis pathogenesis by regulating keratinocyte stress response and apoptosis (Szell et al., 2016). however, the role of lncRNAs in the psoriasis immune abnormalities has not been reported. To date, studies have indicated that lncRNAs are involved in DC differentiation and activation of innate immune response (Wang et al., 2014; Xu et al., 2019). Moreover, lncRNAs play important role in T cell differentiation and immune-related diseases (Roy & Awasthi, 2019). They exhibit cell- and tissue-specific expression (Liu et al., 2017; Tsoi et al., 2015). Given this, immune-related lncRNAs may be used as potential diagnostic and prognostic biomarkers for psoriasis.

In recent years, bioinformatics analysis has provided new insight into the molecular mechanism and therapeutic targets in psoriasis (Anbunathan & Bowcock, 2017). Weighted gene coexpression network analysis (WGCNA) has been used to identify potential biomarkers for psoriasis (Sundarrajaj & Arumugam, 2016). In our previous study, WGCNA was used to identify potential key mRNAs and lncRNAs for psoriasis (Li et al., 2020). However, immune-related lncRNAs in the pathogenesis of psoriasis and the correlation between immune-related lncRNAs and treatment response have been relatively neglected.
In this study, we screened differentially expressed genes (DEGs) and differentially expressed immune-related genes (DEIRGs) from training set and identified immune-related lncRNA biomarkers using coexpression analysis. Next, we validated the diagnostic efficacy of 10 lncRNAs and its correlation with biologics response using 2 validation sets, respectively. In addition, we investigated the correlation between infiltrated immune cells and immune-related lncRNAs. A total of 394 differentially expressed genes (DEGs) and 76 DEIRGs were extracted from the gene expression profile. Coexpression analysis identified 16 immune-related lncRNAs. Of 16 immune-related lncRNAs, 10 lncRNAs were identified as potential diagnostic biomarkers for psoriasis using LASSO logistic regression algorithms.

Materials & Methods

Gene expression data processing

The psoriasis gene expression profile datasets GSE13355 (Nair et al., 2009), GSE30999 (Correa da Rosa et al., 2017; Suárez-Fariñas et al., 2012), and GSE106992 (Brodmerkel et al., 2019) were downloaded from Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) using the GEOquery (Davis & Meltzer, 2007) package of R software (version 3.6.5, http://r-project.org/). All samples of the datasets were derived from Homo sapiens, and the platform was based on GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. Affymetrix includes 47,400 probes and represents 38,500 human genes. Gene biotypes were extracted using the BioMart (Durinck et al., 2009). Gene biotypes were used to distinguish lncRNAs, miRNAs and mRNAs, and the expression matrix of lncRNAs was extracted separately. There are 1313 lncRNAs on the Affymetrix Human Genome U133 Plus 2.0. GSE13355 consisted of 58 psoriasis lesion samples, adjacent normal skin samples, and 64 normal skin samples from normal controls. GSE30999 consisted of 85 psoriasis lesion samples and adjacent normal skin samples. GSE106992 consisted of 192 skin samples of moderate to severe psoriasis patients undergoing ustekinumab (a monoclonal antibody directed against the P40 unit of IL-12 and IL-23) or etanercept (a TNF antagonist) therapy. Patients were categorized as responders and nonresponders. Responders vs nonresponders was determined based on whether the PASI75 score was reached following treatment with ustekinumab or etanercept for 12 weeks. All 3 datasets were included in this study. The raw data of GSE13355, GSE30999, and GSE106992 datasets were read using the affy package (Gautier et al., 2004).

Background correction and normalization were performed, and distinguishable lncRNA and mRNA gene expression matrices were obtained. z-score normalization for GSE13355 dataset was performed using the limma package. The effect of correction was presented using principal component analysis (PCA) using ggplot2 package (Ginestet, 2011). GSE13355 was used as training set whereas GSE30999 and GSE106992 were used as validation sets. This study did not involve studies on human participants or animals performed by any of the authors.

Screening of differentially expressed genes

The limma package (Ritchie et al., 2015) was used to screen GSE13355 dataset DEGs by comparing lesion samples, adjacent normal skin samples, and normal controls. A cutoff value of
adjusted P<.05 and |log2FC|>1 was considered statistically different. Subsequently, volcano plot

121 Functional and pathway enrichment analysis of DEGs

122 Gene Ontology (GO) serves as a powerful tool to annotate genes and analyze related biological
123 processes of genes, and Kyoto Encyclopedia of Genes and Genomes (KEGG) is a bioinformatics
124 resource for understanding high-level functions and utilities of the biological system. GO and
125 KEGG analyses of DEGs were performed using clusterProfiler package (Yu et al., 2012),
126 adjusted P<.05 was considered statistically significant. Gene set enrichment analysis (GSEA) is a
127 statistical approach for determining whether the genes from particular pathways or other
128 predefined gene sets are differentially expressed in different phenotypes (Subramanian et al.,
129 2005). Reactome pathways were analyzed with GSEA, using clusterProfiler (Yu et al., 2012) to
129 define every functional cluster. “c2.cp.kegg.v7.0.symbols.gmt” was selected as reference set, and
131 false discovery rate (FDR) <0.25 with P<.05 was considered significantly enriched.

132 Screening of immune-related genes and immune-related IncRNAs

133 The list of immune-related genes (IRGs) was downloaded from ImmPort
134 (https://immport.niaid.nih.gov) database (Bhattacharya et al., 2018). DEIRGs from DEGs were
135 identified, and volcano plots (differential expression of DEIRGs) were plotted using ggplot2
136 package. Immune-related IncRNAs were screened using coexpression analysis of DEIRG and
137 IncRNA expression matrices. Correlation coefficients >.4 with P<.05 was considered as
138 coexpression (Xiong et al., 2019; Deforges et al., 2019). Likewise, target genes were screened
139 using coexpression analysis of IncRNA and mRNA expression matrices.

140 GO and KEGG enrichment analyses of IRGs and immune-related IncRNAs

141 To analyze the functions of IRGs and immune-related IncRNAS, GO and KEGG enrichment
142 analyses were performed using clusterProfiler, and adjusted P<.05 was considered statistically
143 significant.

144 Screening and validation of immune-related IncRNA biomarkers

145 Biomarkers of psoriasis were screened using LASSO logistic regression feature selection
146 algorithm (Tibshirani, 1996) based on immune-related IncRNA expression matrices. We used a
147 LASSO-logitstic-algorithm model; further, a 10-fold cross-validation was used to identify the
148 optimal lambda value. Diagnostic performances were validated using GSE30999 dataset as
149 validation sets, an AUC value >0.7 was determined to indicate acceptable diagnostic efficacy
150 (Watson et al., 2015; Bhardwaj et al., 2020), whereas the correlation between IncRNA
151 biomarkers and therapeutic response was validated using GSE106992 dataset.

152 Assessment of immune cell infiltration and the correlation between biomarkers and
153 immune cells

154 To estimate the composition and abundance of immune cells in the mixed cells, deconvolution of
155 transcriptome expression matrices was performed using CIBERSORT (Newman et al., 2015)
156 based on linear support vector regression. Expression matrices were uploaded to CIBERSORT,
157 and immune cell infiltration matrices were generated with cutoff value of P<.05. Heatmap was
158 generated using R language “pheatmap” package (https://CRAN.R-
project.org/package=pheatmap) to visualize 22 infiltrated immune cells in each sample. Two-dimensional PCA plots were visualized using ggplots, and heatmap was plotted using the corrplot package (Friendly, 2002) to visualize the correlation of 22 immune cell types. Violin plots were generated using ggplot2 package to visualize the infiltration difference of 22 immune cell types. Infiltrating immune cells–related network plots were generated using igraph package (Ju et al., 2016) to visualize the interactions of infiltrated immune cells. P<.05 and correlation coefficients >0.4 were considered statistically significant. Correlation analysis was performed between immune-related IncRNA biomarkers and infiltrated immune cells. Afterwards, results were visualized using ggplot2 package.

Results

Gene expression data preprocessing and DEGs identification

Figure 1 represents the study flowchart. Primarily, gene expression matrices of GSE13355 dataset were normalized. PCA was plotted before and after normalization (Figure 2A and 2B). The results indicated that sample clustering was more apparent after normalization, which indicated that the sample source was reliable. A total of 394 DEGs were extracted from gene expression profile using R software after data preprocessing, as shown in the volcano plot (Figure 2C). The details of top 10 upregulated and downregulated differently expressed genes are presented in Table 1 and Table 2.

Functional and pathway enrichment analysis of DEGs

GO analysis revealed that DEGs were primarily associated with epidermis development, skin development, secretory granule lumen, and receptor ligand activity (Figure 3A). The results of KEGG analysis indicated that DEGs were mainly enriched in cytokine-cytokine receptor interaction and IL-17 signaling pathway (Figure 3B). GESA suggested that psoriasis was mainly involved in IL-17 signaling pathway and proteasome pathway (Figure 3C). CCL2, CCL7, CCL20, PSMB8, PSMB9, and PSMB10 played important roles in signal transduction of the 2 pathways. Detailed enrichment results were presented in Supplemental Table 1.

Identification of IRGs and immune-related IncRNAs

A total of 76 DEIRGs were extracted from gene expression profile, as shown in volcano plots and heatmap (Figure 4A and FigureS1), these data only refer to GSE13355, and detailed results of GO analysis of 76 DEIRGs are presented in Supplemental Table 2. Coexpression analysis identified 16 immune-related IncRNAs, which are part of the 394 DEGs. The detailed results of KEGG analysis of 16 immune-related IncRNAs are presented in Table 3.

Functional and pathway enrichment analysis of immune-related IncRNAs

GO enrichment analysis of target genes found that immune-related IncRNAs were primarily associated with epidermis development, skin development, collagen-containing extracellular matrix, and glycosaminoglycan binding (Figure 4B), and KEGG enrichment analysis of target genes found that immune-related IncRNAs were mainly enriched in cytokine-cytokine receptor interaction and influenza A and chemokine signaling pathway (Figure 4C). Detailed results of immune-related IncRNAs target gene functional correlation analysis are presented in
Identification and validation of diagnostic biomarkers

Of 16 immune-related lncRNAs, 10 lncRNAs were identified as potential diagnostic biomarkers for psoriasis using LASSO logistic regression algorithms (Figure 5A). Detailed LASSO results are presented in Supplemental Table 5. To further assess diagnostic efficacy, we performed validation using GSE30999 dataset. The ROC curve (Figure 5B and 5C) indicated that LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMN, CCDC18-AS1, EPB41L4A-AS, and LINC01214 exhibited well diagnostic efficacy (AUC>0.7), which indicated high diagnostic value of the screened lncRNA biomarkers. The details of the AUC and 95% CI of AUC of the 10 immune-related lncRNAs are presented in Table 4.

Analysis of relation between screened biomarkers and biologics therapeutic response

Results of drug response (Figure 6) indicated that LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMN, CCDC18-AS1, EPB41L4A-AS, and LINC01214 were significantly expressed between the responders and nonresponders groups, which was statistically significant (P<.00001). The expression of LINC01137, LINC01215, and LINC01214 was higher in the responders group.

Analysis of immune cell infiltration and correlation assessment of immune cells and diagnostic biomarkers

Heatmap of immune cell infiltration and results of cluster PCA indicated a significant difference between the psoriasis group and control group (Figure 7A and 7B). Heatmap of 22 immune cells indicated that psoriasis was positively correlated with activated memory CD4+T cell, activated myeloid DC, neutrophils, and T follicular helper (Tfh) cells, while negatively correlated with T regulatory cell (Tregs) and activated mast cell. Violin plots of immune cell infiltration difference (Figure 8A) indicated that naïve B cell, CD8+T cell, activated memory CD4+T cell, Tfh cell, T gamma delta cell, NK cell resting, macrophage M0, macrophage M1, activated myeloid DC, and neutrophil were higher than normal control, whereas B cell memory, B cell plasma, T cell CD4+ naïve, Tregs, activated NK cell, and activated mast cell were lower. Plots of 22 immune cells interaction (Figure 8B) indicated that activated mast cell exhibited the strongest interaction with other immune cells, whereas CD8+T cell and monocyte were the weakest. Results of the correlation analysis indicated that activated memory CD4 T cell, activated myeloid DC, neutrophil, and Tfh were significantly positively correlated with LINC01137, CCDC18-AS1, and CARMN, while negatively correlated with LINC01215, MAPKAPK5-AS1, LINC01305, DUBR, TPT1-AS1, EPB41L4A-AS, and LINC01214. In addition, Tregs and activated mast cell were found to be significantly negatively correlated with LINC01137, CCDC18-AS1, and CARMN, while positively correlated with LINC01215, MAPKAPK5-AS1, LINC01305, DUBR, TPT1-AS1, EPB41L4A-AS, and LINC01214.

Discussion
Psoriasis is a chronic immune-mediated inflammatory dermatosis that significantly affects patients’ quality of life (Alexander & Nestle, 2017). To date, the specific pathogenesis is unclear. Crosstalk of keratinocytes and immune cells including DCs, T cells, mast cells, and neutrophils plays an important role in the pathogenesis of psoriasis, Cytokine-cytokine receptor pathway transmits intercellular interactions, with IL-23/IL-17 pathway currently being the most investigated (Chiricozzi et al., 2018). IncRNAs are closely associated with immune-related diseases (Roy & Awasthi, 2019); however, the role of IncRNAs in psoriasis immune abnormalities remains elusive. In our study, we explored the potential biological and diagnostic efficacy of immune-related IncRNAs in psoriasis.

This study aimed to identify key immune-related IncRNAs involved in the pathogenesis of psoriasis. We performed systematic analysis of expression profile from GSE13355 dataset; 16 immune-related IncRNAs were identified using coexpression analysis for further analysis. GO analysis has found that identified IncRNAs were enriched in biological processes related to epidermis development, skin development, and collagen-containing extracellular matrix, and KEGG analysis has found that identified IncRNAs were associated with cytokine-cytokine receptor interaction and influenza A and chemokine signaling pathway, consistent with the previous study (Li & Meng, 2019). Some studies have indicated that IncRNAs can regulate the expression of cytokines and chemokines (Dong et al., 2020; Qi et al., 2020). Previous studies have indicated that cytokine-cytokine interaction and chemokine pathway play a crucial role in the pathogenesis of psoriasis (Benezeder & Wolf, 2019). However, the role of influenza A pathway in psoriasis has not yet been reported. Therefore, based on our findings, we suggested that these identified immune-related IncRNAs may be involved in the pathogenesis of psoriasis by regulating cytokine-cytokine interaction and chemokine pathway.

Previous studies have found that some key genes or proteins may serve as potential biomarkers for psoriasis (Dand et al., 2019; Yadav, Singh, & Singh, 2018). However, immune-related IncRNA biomarkers for psoriasis have not yet been reported. Of the 16 immune-related IncRNAs, 10 IncRNAs were identified as potential diagnostic biomarkers for psoriasis using LASSO algorithms. To further assess the diagnostic efficacy, we performed validation using GSE30999 dataset. ROC curve indicated that LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMN, CCDC18-AS1, EPB41L4A-AS, and LINC01214 exhibited well diagnostic efficacy (AUC>0.7), which indicated high diagnostic value of the screened IncRNA biomarkers.

Although the appearance of novel biologics such as TNF inhibitor, IL-12/23 inhibitor, IL-17A/IL-17RA inhibitor, and phosphodiesterase 4 (PD4) inhibitor has improved treatment efficacy, treatments is far from optimal because of higher medical expenses or no response to biologics therapy or residual lesions after treatment or clinical recurrence (Masson Regnault et al., 2017; Sawyer et al., 2019). Therefore, early evaluation of the response to biologics treatment is important. This study also aimed to validate the correlation between immune-related IncRNAs and response to biologics therapy. Results of drug response indicated that LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMNCCDC18-AS1, EPB41L4A-AS, and LINC01214 were differentially expressed between the responders and nonresponders groups.
This difference was statistically significant where the expression of LINC01137, LINC01215, and LINC01214 was higher in the responders group. These results indicate that LINC01137, LINC01215, and LINC01214 may act as potential prognostic biomarkers for monitoring therapeutic response.

To date, there are only a few studies on these lncRNAs. LINC01137 showed upregulated expression in human HepG2 cells when exposed to chemical stress (Tani et al., 2019). The function of LINC01137 still remains to be determined. LINC01215 acted as a hub gene involved in the rehabilitation process through the T cell receptor signaling pathway in respiratory syncytial virus infection (Qian, Zhang, & Wang, 2019). LINC01214 was overexpressed in non-small cell lung carcinoma (Acha-Sagredo et al., 2020). However, its exact function remains unknown.

As an immune-related lncRNA, MAPKAPK5-AS1 may act as a prognostic biomarker for anaplastic gliomas (Wang et al., 2018). Another study found that MAPKAPK5-AS1 was significantly overexpressed in colorectal cancer and played a role by inhibiting P21 expression (Ji et al., 2019). Its immunologic mechanisms have not yet been reported. In addition, involvement of CARMN, TPT1-AS1, and EPB41L4A-AS in cancer pathogenesis were reported (Jiang et al., 2018; Kouhsar et al., 2019; Roychowdhury et al., 2020). There has been no report of CCDC18-AS1 in the literature.

To further validate the correlation between immune-related lncRNAs diagnostic biomarkers and infiltrating immune cells, CIBERSORT was applied to estimate the infiltrating immune cells in psoriasis. In immune cell infiltration matrices, increased activated memory CD4+ T cell, activated myeloid DC, neutrophil, and Tfh cell were observed, whereas Treg decreased in psoriatic lesions, consistent with previous studies. Psoriasis is an immune-driven dermatosis (Benhadou, Mintoff, & Del Marmol, 2019). The IL-23/IL17 axis is the main immune pathway in the pathogenesis of psoriasis, and the main immune cells involved in psoriasis include CD4+ T cells, DCs, neutrophils, macrophages, and Tfh (Chiricozzi et al., 2018). Tregs are important in suppressing the immune response, whereas they decrease in psoriatic lesions (Yang et al., 2016).

Of the LINC01137, CCDC18-AS1, CARMN, LINC01215, MAPKAPK5-AS1, TPT1-AS1, EPB41L4A-AS, and LINC01214, LINC01137, CCDC18-AS1, and CARMN were positively correlated with activated memory CD4 T cell, activated myeloid DC, neutrophil, macrophage M1, and Tfh, while negatively correlated with Treg. In addition, LINC01215, MAPKAPK5-AS1, TPT1-AS1, EPB41L4A-AS, and LINC01214 were negatively correlated with activated memory CD4 T cell, activated myeloid DC, neutrophil, macrophage M1, and Tfh, while positively correlated with Treg. These correlations may partly be explained by LINC01137, CCDC18-AS1, and CARMN that induce activation of CD4+ T cells, myeloid DCs, neutrophils, macrophages, and Tfh cells and exhibit Treg cells involved in the immunopathogenesis of psoriasis, whereas LINC01215, MAPKAPK5-AS1, TPT1-AS1, EPB41L4A-AS, and LINC01214 work in the opposite way.

Our findings suggest that LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMN, CCDC18-AS1, EPB41L4A-AS, and LINC01214 may be potential diagnostic biomarkers for psoriasis and LINC01137, LINC01215, and LINC01214 may serve as predictive.
biomarkers for biologics response in psoriasis. These immune-related lncRNAs may involve in
the immunopathogenesis of psoriasis by activating or inhibiting related immune cells.

In the past few years, psoriasis genome-wide association studies (GWAS) have been
conducted worldwide, and numbers of genetic loci associated with psoriasis susceptibility have
been estimated (Ogawa & Okada, 2020). Previews studies showed that approximately 10% of
autoimmune disease-associated SNPs localize to IncRNA genes present in autoimmune disease-
associated loci, and SNPs can affect the expression of IncRNAs (Kumar et al., 2013). Therefore,
as a future prospect, identifying whether these estimated immune-related IncRNAs biomarkers
contain psoriasis-related SNPs identified by GWAS will be worthwhile.

This study has some limitations. First, these results were generated by bioinformatics
analysis and need further experimental verification. Second, a larger sample size of the dataset is
needed for internal validation. Third, additional clinical information is needed to explore the
correlation between immune-related IncRNAs and clinical severity. Fourth, Th17 is a CD4+T
cell subtype; further, because the 22 immune-infiltrating cells estimated by CIBERSORT were
not specific to the Th17 subgroup, Th17 cells were not observed in immune cell infiltration.
Finally, the normal control group needs to be involved to analyze the differentially expressed
immune-related IncRNAs.

Conclusions
We found that LINC01137, LINC01215, MAPKAPK5-AS1, TPT1-AS1, CARMN, CCDC18-
AS1, EPB41L4A-AS, and LINC01214 may be potential diagnostic biomarkers for psoriasis.
LINC01137, LINC01215, and LINC01214 may serve as predictive biomarkers for biological
response in psoriasis.

Acknowledgments
The authors would like to thank Enago (www.enago.cn) for the English language review. We
sincerely thank Xuemei Wang for the technical support and useful suggestions.

References
Acha-Sagredo A, Uko B, Pantazi P, Bediaga NG, Moschandrea C, Rainbow L, Liloglou T. 2020.
Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma
pathogenesis. British Journal of Cancer 122(7):1050-1058 DOI 10.1038/s41416-020-0742-9.
Albanesi C, Madonna S, Gisondi P, Girolomoni, G. 2018. The interplay between keratinocytes
and immune cells in the pathogenesis of psoriasis. Frontiers in Immunology 9:1549. DOI
10.3389/fimmu.2018.01549.
Alexander H, Nestle FO. 2017. Pathogenesis and immunotherapy in cutaneous psoriasis: what ca
n rheumatologists learn? Current Opinion in Rheumatology 29(1):71-78 DOI 10.1097/B
OR.0000000000000358.
Anbunathan H, Bowcock AM. 2017. The Molecular Revolution in Cutaneous Biology: The Era
of Genome-Wide Association Studies and Statistical, Big Data, and Computational Topics. *Journal of Investigative Dermatology* 137(5):e113-e118. DOI 10.1016/j.jid.2016.03.047.

Benezeder T, Wolf P. 2019. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). *Seminars in Immunopathology* 41(6):633-644 DOI 10.1007/s00281-019-00766-z.

Benedou F, Mintoff D, Del Marmol V. 2019. Psoriasis: Keratinocytes or Immune Cells - Which Is the Trigger? *Dermatology*, 235(2):91-100 DOI 10.1159/000495291.

Bhardwaj M, Weigl K, Tikk K, Benner A, Schrotz-King P, Brenner H. 2020. Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. *Molecular Oncology* 14(1):8-21 DOI 10.1002/1878-0261.12591.

Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, Butte AJ. 2018. ImmPort, towards repurposing of open access immunological assay data for translational and clinical research. *Scientific Data* 5(1):180015-180015 DOI 10.1038/sdata.2018.15.

Boehncke, WH, Schön MP. 2015. Psoriasis. *The Lancet*, 386(9997), 983-994. DOI 10.1016/s0140-6736(14)61909-7.

Brodmerkel C, Li K, Garcet, S, Hayden K, Chiricozzi A, Novitskaya I, Krueger JG. 2019. Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. *Journal of Allergy and Clinical Immunology* 143(5):1965-1969 DOI 10.1016/j.jaci.2019.01.017.

Cai P, Otten ABC, Cheng B, Ishii MA, Zhang W, Huang B, Sun BK. 2020. A genome-wide long noncoding RNA CRISPRi screen identifies PRANCR as a novel regulator of epidermal homeostasis. *Genome Research* 30(1):22-34 DOI 10.1101/gr.251561.119.

Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. 2018. Scanning the Immunopathogenesis of Psoriasis. *International Journal of Molecular Sciences* 19(1):179-210 DOI 10.3390/ijms19010179.

Correa da Rosa J, Kim J, Tian S, Tomalin LE., Krueger, JG, & Suarez-Farinas M. 2017. Shrinking the psoriasis assessment gap: early gene-expression profiling accurately predicts response to long-term treatment. *Journal of Investigative Dermatology* 137(2):305-312 DOI 10.1016/j.jid.2016.09.015.

Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Consortium P. 2019. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. *Journal of Allergy and Clinical Immunology* 143(6):2120-2130 DOI 10.1016/j.jaci.2018.11.038.

Davis S, Meltzer PS. 2007. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. *Bioinformatics* 23(14):1846-1847 DOI 10.1093/bioinformatics/btm254.

Deforges J, Reis RS., Jacquet P, Sheppard S, Gadekar VP, Hart-Smith G, Tanzer A, Hofacker IL, Iseli C, Xenarios I, Poirier Y. 2019. Control of Cognate Sense mRNA Translation by cis-Natural Antisense RNAs. *Plant Physiology* 180(1):305-322 DOI 10.1104/pp.19.00043.
Dong X, Zhao Z, Hu Y, Lu Y, Liu P, Zhang L. 2020. LncRNA COL1A1-014 is involved in the progression of gastric cancer via regulating CXCL12-CXCR4 axis. *Gastric Cancer* 23(2):260-272 DOI 10.1007/s10120-019-01011-0.

Duan Q, Wang G, Wang M, Chen C, Zhang M, Liu M, Zheng Y. 2020. LncRNA RP6-65G23.1 accelerates proliferation and inhibits apoptosis via p-ERK1/2/p-AKT signaling pathway on keratinocytes. *Journal of Cellular Biochemistry* 121(11):4580-4589 DOI 10.1002/jcb.29685.

Durinck S, Spellman PT, Birney E, Huber W. 2009. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nature Protocols* 4(8):1184-1191 DOI 10.1038/nprot.2009.97.

Gautier L, Cope L, Bolstad BM, Irizarry RA. 2004. affy--analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics*, 20(3):307-315 DOI 10.1093/bioinformatics/btg405.

Ginestet C. 2011. ggplot2: Elegant Graphics for Data Analysis. *Journal of the Royal Statistical Society* 174(1):245-246. DOI 10.1111/j.1467-985X.2010.00676_9.x.

Gupta R, Ahn R, Lai K, Mullins E, Debbaneh M, Dimon M, Liao W. 2016. Landscape of long noncoding RNAs in psoriatic and healthy skin. *Journal of Investigative Dermatology* 136(3):603-609 DOI 10.1016/j.jid.2015.12.009.

Gupta R, Ahn R, Lai K, Mullins E, Debbaneh M, Dimon M, Liao W. 2016. Landscape of long noncoding RNAs in psoriatic and healthy skin. *Journal of Investigative Dermatology* 136(3):603-609 DOI 10.1016/j.jid.2015.12.009.

Ji H, Hui B, Wang J, Zhu Y, Tang L, Peng P, Wang K. 2019. Long noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer proliferation by partly silencing p21 expression. *Cancer Science* 110(1):72-85 DOI 10.1111/cas.13838.

Kopp F, Mendell JT. 2018. Functional classification and experimental dissection of long noncoding RNAs. *Cell* 172(3):393-407 DOI 10.1016/j.cell.2018.01.011.

Kouhsar M, Azimzadeh Jamalkandi S, Moeini A, Masoudi-Nejad A. 2019. Detection of novel biomarkers for early detection of Non-Muscle-Invasive Bladder Cancer using Competing Endogenous RNA network analysis. *Science Reports* 9(1):8434-8449 DOI 10.1038/s41598-019-44944-3.

Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, Khavari PA. 2013. Control of somatic tissue differentiation by the long non-coding RNA TINCR. *Nature* 493(7431):231-235 DOI 10.1038/nature11661.

Kretz M, Webster DE, Flockhart RJ, Lee CS, Zehnder A, Lopez-Pajares V, Khavari PA. 2012. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. *Genes and Development* 26(4):338-343 DOI 10.1101/gad.182121.111.
Kumar V, Westra HJ, Karjalainen J, Zhernakova DV, Esko T, Hrdlickova B, Wijmenga C. 2013. Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. *PLoS Genetics* 9(1): e1003201 DOI 10.1371/journal.pgen.1003201.

Li H, Yang C, Zhang J, Zhong W, Zhu L, Chen Y. 2020. Identification of potential key mRNAs and LncRNAs for psoriasis by bioinformatic analysis using weighted gene co-expression network analysis. *Molecular Genetics and Genomics* 295(3):741-749 DOI 10.1007/s00438-020-01654-0.

Li X, Meng Y. 2019. Survival analysis of immune-related LncRNA in low-grade glioma. *BMC Cancer* 19(1):813-819 DOI 10.1186/s12885-019-6032-3.

Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, Attenello FJ, Villalta JE, Cho MY, Chen Y, Mandegar MA, Olvera MP, Gilbert LA, Conklin BR, Chang HY, Weissman JS, Lim DA. 2017. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. *Science*, 355(6230):39-55 DOI 10.1126/science.aah7111.

Masson Regnault M, Konstantinou MP, Khemis A, Poulin Y, Bourcier M, Amelot F, Paul C. 2017. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. *Journal of the European Academy of Dermatology and Venereology* 31(9):1491-1496 DOI 10.1111/jdv.14387.

Michalek IM, Loring B, John SM. 2017. A systematic review of worldwide epidemiology of psoriasis. *Journal of the European Academy of Dermatology and Venereology*, 31(2), 205-212. DOI 10.1111/jdv.13854.

Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. *Nature Genetics* 41(2):199-204 DOI 10.1038/ng.311.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. 2015. Robust enumeration of cell subsets from tissue expression profiles. *Nature Methods* 15(5):453-457 DOI 10.1038/nmeth.3337.

Ogawa K, Okada Y. 2020. The current landscape of psoriasis genetics in 2020. *Journal of Dermatological Science* 99(1):2-8 DOI 10.1016/j.jdermsci.2020.05.008.

Qi Y, Wu H, Mai C, Lin H, Shen J, Zhang X, Xie X. 2020. LncRNA-MIAT-Mediated miR-214-3p Silencing Is Responsible for IL-17 Production and Cardiac Fibrosis in Diabetic Cardiomyopathy. *Frontiers in Cell and Developmental Biology* 8:243 DOI 10.3389/fcell.2020.00243.

Qian Z, Zhang Z, Wang Y. 2019. T cell receptor signaling pathway and cytokine-cytokine receptor interaction affect the rehabilitation process after respiratory syncytial virus infection. *PeerJ*, 7, e7089 DOI 10.7717/peerj.7089.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* 43(7):e47 DOI 10.1093/nar/gkv007.

Roy S, Awasthi A. 2019. Emerging roles of noncoding RNAs in T cell differentiation and functi
ons in autoimmune diseases. *International Reviews of Immunology* 38(5):232-245 DOI 10.1080/08830185.2019.1648454.

Roychowdhury A, Samadder S, Das P, Mazumder DI, Chatterjee A, Addya S, Panda CK. 2020. Deregulation of H19 is associated with cervical carcinoma. *Genomics*, 112(1):961-970 DOI 10.1016/j.ygeno.2019.06.012.

Sawyer LM, Cornic L, Levin LA, Gibbons C, Moller AH, & Jemec GB. 2019. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. *Journal of the European Academy of Dermatology and Venereology* 33(2):355-366 DOI 10.1111/jdv.15277.

Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. 2012. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. *Journal of Investigative Dermatology* 132(11): 2552-2564 DOI 10.1038/jid.2012.184.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences USA* 102:15545-15550 DOI 10.1073/pnas.0506580102.

Sundarrajan S, Arumugam M. 2016. Weighted gene co-expression based biomarker discovery for psoriasis detection. *Gene*, 593(1):225-234 DOI 10.1016/j.gene.2016.08.021.

Szell M, Danis J, Bata-Csorgo Z, Kemeny L. 2016. PRINS, a primate-specific long non-coding RNA, plays a role in the keratinocyte stress response and psoriasis pathogenesis. *Pflügers Archiv : European Journal of Physiology* 468(6):935-943 DOI 10.1007/s00424-016-1803-z.

Tani H, Numajiri A, Aoki M, Umemura T, Nakazato T. 2019. Short-lived long noncoding RNAs as surrogate indicators for chemical stress in HepG2 cells and their degradation by nuclear RNases. *Scientific Reports* 9(1):1-10 DOI 10.1038/s41598-019-56869-y.

Tibshirani R. 1996. Regression Shrinkage and Selection Via the Lasso. *Journal of the Royal Statistical Society*, 58(1):267-288 DOI 10.1111/j.2517-6161.1996.tb02080.x.

Tsoi LC, Iyer MK, Stuart PE, Swindell WR., Gudjonsson JE, Tejasvi T, Elder JT. 2015. Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. *Genome Biology* 16(1):24-39 DOI 10.1186/s13059-014-0570-4.

Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, Jiang Z, Xu J, Liu Q, Cao X. 2014. The STAT3-binding long noncoding RNA Inc-DC controls human dendritic cell differentiation. *Science*, 344(6181):310-313 DOI 10.1126/science.1251456.

Wang W, Zhao Z, Yang F, Wang H, Wu F, Liang T, Zhao J. 2018. An immune-related lncRNA signature for patients with anaplastic gliomas. *Journal of Neurooncology* 136(2):263-271 DOI 10.1007/s11060-017-2667-6.

Watson CJ, Gupta SK, O’Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M,
Grote-Levi L, McDonald K, Thum T. 2015. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. *European Journal of Heart Failure* 17(4): 405-415 DOI 10.1002/ejhf.244.

Xiong H, Li H, Xiao Y, Yang Q, Yang L, Chen L, Bu L, Zhang W, Zhang J, Sun Z. (2019). Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. *Journal of Experimental and Clinical Cancer Research* 38(1):278. DOI 10.1186/s13046-019-1254-4.

Xu, H, Jiang, Y, Xu X, Su X, Liu Y, Ma, Y, Cao X. 2019. Inducible degradation of lncRNA Sros1 promotes IFN-gamma-mediated activation of innate immune responses by stabilizing Stat1 mRNA. *Nature Immunology* 20(12):1621-1630 DOI 10.1038/s41590-019-0542-7.

Yadav K, Singh D, Singh MR. 2018. Protein biomarker for psoriasis: A systematic review on the ir role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis. *International Journal of Biological Macromolecules* 118:1796-1810.DOI 10.1016/j.ijbiomac.2018.07.021.

Yang L, Li B, Dang E, Jin L, Fan X, Wang G. 2016. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. *Journal of Dermatological Science* 81(2):85-92 DOI 10.1016/j.jdermsci.2015.11.007.

Yu G, Wang L, Han Y, He Q. 2012. clusterProfiler: an R package for comparing biological the mes among gene clusters. *OMICS* 16(5): 284-287 DOI 10.1089/omi.2011.0118.
Figure 1

A flowchart of the GEO datasets analysis.

Flowchart of the datasets analysis.

GSE13355 (58 psoriasis lesion samples v 64 normal skin samples)

Screening of differentially expressed genes

394 differentially expressed genes (DEGs) were extracted

76 differentially expressed immune-related genes (DEIRGs) from DEGs were identified

Coexpression analysis

16 immune-related IncRNAs were identified

LASSO logistic regression

10 IncRNAs were identified as diagnostic biomarkers

assess diagnostic efficacy using GSE30999 dataset

immune-related genes (IRGs) were downloaded from ImmPort

IncRNA expression matrices

correlation between IncRNA biomarkers and therapeutic response was validated using GSE106992 dataset.
Figure 2

Density map and PCA plot before and after normalization of GSE13355 dataset.

(A, B) PCA plot before and after the batch effect removal, respectively. (C) Volcano plot of DEGs; red represents upregulated differential genes, green represents downregulated differential genes, and gray represents no differential genes.
Figure 3

Functional and pathway enrichment analysis of DEGs

(A) GO enrichment analysis of biological functions. The x-axis represents the proportion of DEGs enriched in GO team. Dot color indicates corrected P values: the brighter the red color, the smaller the corrected P values, and the brighter the blue color, the bigger the corrected P values. Dot size represents the number of enriched genes. (B) KEGG pathway analysis; Significantly enriched KEGG pathways obtained. (C) Gene enrichment analysis; P value was calculated using Kolmogorov-Smirnov test. BP: biological process, MF: molecular function, CC: cell component. GeneRatio: the ratio of the number of genes related to this Term in the differential gene to the total number of the differential genes.
Figure 4

Volcano plot, heatmap of differentially expressed immune-related genes (DEIRGs), and lncRNA functional annotation.

(A) Volcano plot of DEIRGs; red represents upregulated differential genes, green represents downregulated differential genes, and gray represents no differential genes. (B) GO analysis of immune-related lncRNA target genes. (C) KEGG analysis of immune-related lncRNA target genes. The x-axis represents the proportion of DEGs enriched in GO team. Dot color indicates corrected P values: the brighter the red color, the smaller the corrected P values; the brighter the blue color, the bigger the corrected P values. Dot size represents the number of enriched genes.
Figure 5

Diagnostic biomarker identification and validation.

(A) 10 IncRNAs were identified as potential diagnostic biomarkers for psoriasis by LASSO logistic regression algorithms with 10-fold cross-validation. (B, C) ROC curve for diagnostic biomarker in test dataset.
**Figure 6**

Heatmap of diagnostic biomarker and biologics response correlation analysis.

Heatmap of diagnostic biomarker and biologics response correlation analysis. ****P < .00001

| Subtype                | P-value  |
|------------------------|----------|
| LINC01137****          | 4.02e-12 |
| LINC01215****          | 1.90e-11 |
| MAPKAPK5.AS1****       | 3.33e-04 |
| TPT1.AS1****           | 3.43e-06 |
| CARMN****              | 1.04e-05 |
| CCDC18.AS1****         | 4.02e-12 |
| DUBR                   | 8.59e-01 |
| EPB41L4A.AS1****       | 8.81e-06 |
| LINC01214****          | 1.69e-10 |
| LINC01305              | 7.61e-01 |
Figure 7

Assessment and visualization of immune cell infiltration.

(A) Heatmap of differentially infiltration of immune cells between psoriasis group and control group. (B) PCA plots show the clustering of immune cell infiltration in the psoriasis group and control group. (C) Heatmap of correlation of infiltration between 22 immune cells. Blue indicates positive correlation, whereas red indicates negative correlation; the darker the color, the stronger the correlation.
Figure 8

Visualization of immune cell infiltration and correlation analysis with diagnostic biomarker.

(A) Violin plots of the proportion of infiltration of 22 immune cells. Red represents the psoriasis group, and blue represents the control group. (B) Interaction plots of infiltration of 22 immune cells. The size of the circle represents interaction strength; the bigger the circle, the stronger the interaction. (C) The correlation analysis of infiltration between 22 immune cells and immune-related IncRNA diagnostic biomarkers; red represents positive correlation, and blue represents negative correlation.
Table 1 (on next page)

The top 10 differentially expressed genes (up regulated)

logFC and p value of these top 10 up regulated differentially expressed genes were presented in table
| Gene symbol | logFC   | P-value   | adj P-value |
|-------------|---------|-----------|-------------|
| SERPINB4    | 6.553829| 1.98E-82  | 3.44E-79    |
| PI3         | 5.404915| 8.91E-107 | 1.86E-102   |
| TCN1        | 4.999575| 6.35E-94  | 2.65E-90    |
| SPRR2C      | 4.709046| 4.24E-93  | 1.26E-89    |
| S100A12     | 4.677867| 4.94E-105 | 5.15E-101   |
| AKR1B10     | 4.568268| 5.91E-94  | 2.65E-90    |
| SERPINB3    | 4.389195| 3.26E-79  | 4.53E-76    |
| S100A9      | 4.388357| 1.97E-71  | 1.18E-68    |
| IL36G       | 4.072299| 1.21E-88  | 3.16E-85    |
| C10orf99    | 3.962806| 4.10E-75  | 3.88E-72    |
Table 2 (on next page)

The top 10 differentially expressed genes (down regulated)

logFC and p value of these top 10 down regulated differentially expressed genes were presented in table
| Gene symbol | logFC  | P-value  | adj P-value |
|------------|-------|----------|-------------|
| WIFI1      | -3.98135 | 2.64E-53 | 2.54E-51    |
| BTC        | -3.27259 | 1.33E-50 | 1.07E-48    |
| CCL27      | -3.22479 | 8.40E-59 | 1.33E-56    |
| KRT77      | -3.21433 | 5.75E-63 | 1.43E-60    |
| IL37       | -3.03789 | 1.49E-57 | 2.11E-55    |
| C5orf46    | -2.75129 | 3.38E-61 | 6.77E-59    |
| THRSP      | -2.6802  | 7.85E-20 | 6.04E-19    |
| MSMB       | -2.59999 | 5.13E-35 | 1.19E-33    |
| PM20D1     | -2.56708 | 4.88E-12 | 2.09E-11    |
| ELOVL3     | -2.43197 | 4.72E-14 | 2.35E-13    |
Table 3 (on next page)

The details of 16 immune-related IncRNAs

The gene symbol, gene type, description, location and phenotypes of the 16 immune-related IncRNAs.
## Table 3. The details of the 16 immune-related lncRNAs

| Gene symbol | Gene type | Correlation coefficients | P value       | Location                              | Phenotypes                           |
|-------------|-----------|---------------------------|---------------|---------------------------------------|---------------------------------------|
| LINC01214   | LncRNA    | 0.832                     | 2.13E-47      | Chr3:150,265,407-150,296,65            | No report                             |
| LINC01215   | LncRNA    | 0.842                     | 1.09E-49      | Chr3: 108,125,821-108,138,610         | No report                             |
| LINC01137   | LncRNA    | 0.861                     | 4.43E-54      | Chr1: 37,350,934-37,474,411           | Vaccinia virus infection              |
| LINC01305   | LncRNA    | 0.710                     | 5.72E-29      | Chr2: 174,326,027-174,330,643         | epithelial-mesenchymal transition     |
| CARMN       | LncRNA    | 0.779                     | 5.65E-38      | Chr5: 149,406,689-149,432,835         | Vaccinia virus infection              |
| CCDC18-AS1  | LncRNA    | 0.724                     | 1.56E-30      | Chr1: 93,262,186-93,346,025           | No report                             |
| DUBR        | LncRNA    | 0.754                     | 2.53E-34      | Chr3: 107,220,744-107,348,464         | No report                             |
| EPB4L4A-AS  | LncRNA    | 0.772                     | 7.94E-37      | Chr5: 112,160,526-112,164,818         | metabolic reprogramming               |
| MAPKAPK5-AS1| LncRNA    | 0.795                     | 2.03E-40      | Chr12:111,839,764-111,842,902         | tumorigenesis                         |
| TPT1-AS1    | LncRNA    | 0.766                     | 5.65E-36      | Chr13: 45,341,345-45,417,975          | tumor promotion                       |
| PGM5-AS1    | LncRNA    | 0.854                     | 1.81E-52      | Chr9: 68,353,614-68,357,893           | tumor suppression                     |
| SH3PXD2A-AS1| LncRNA    | 0.909                     | 1.50E-69      | Chr10:103,745,966-103,755,423         | tumor promotion                       |
| LINC00173   | LncRNA    | 0.745                     | 4.26E-33      | Chr12:116,533,422-116,536,518         | chemoresistance                      |
| LINC00518   | LncRNA    | 0.731                     | 2.61E-31      | Chr6: 10,429,255-10,435,015           | tumor promotion, chemoresistance      |
| LINC00526   | LncRNA    | 0.755                     | 1.68E-34      | Chr18: 5,236,724-5,238,598            | tumor suppression                     |
| EMX2OS      | LncRNA    | 0.811                     | 2.36E-43      | Chr2: 117484293-117545068             | No report                             |
Table 4 (on next page)

The details of the AUC and 95% CI of AUC of the 10 immune-related IncRNAs

The gene symbol, AUC and 95% CI of AUC of the 10 immune-related IncRNAs.
| Gene symbol    | AUC   | 95% CI of AUC      |
|---------------|-------|--------------------|
| LINC01137     | 0.944 | 0.907-0.982        |
| LINC01215     | 0.953 | 0.919-0.987        |
| MAPKAPK5-AS1  | 0.762 | 0.688-0.835        |
| TPT1-AS1      | 0.822 | 0.758-0.887        |
| CARMN         | 0.854 | 0.797-0.911        |
| CCDC18-AS1    | 0.957 | 0.929-0.985        |
| DUBR          | 0.56  | 0.474-0.647        |
| EPB41L4A-AS1  | 0.894 | 0.846-0.942        |
| LINC01214     | 0.964 | 0.937-0.991        |
| LINC01305     | 0.544 | 0.457-0.631        |